Determination of the level of valproic acid in the blood against the background of the combined use of valproates with ertapenem in pediatric practice
- Authors: Strok A.B.1,2, Chenkurov M.S.1, Kostyleva M.N.3,4, Umutkuzina D.A.5
-
Affiliations:
- «Peoples' Friendship University of Russia (PFUR) named after Patrice Lumumba»
- «Russian Children's Clinical Hospital is a Branch of the «N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation»
- «Russian Children's Clinical Hospital is a Branch of the «N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
- "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
- City Clinical Hospital named after M.E. Zhadkevich
- Issue: Vol 26, No 11 (2023)
- Pages: 74-79
- Section: Medical chemistry
- URL: https://journals.eco-vector.com/1560-9596/article/view/623589
- DOI: https://doi.org/10.29296/25877313-2023-11-12
- ID: 623589
Cite item
Abstract
The article presents a clinical case of the combined use of valproic acid and an antibacterial drug from the carbapenem group – ertapenem in a 15-year-old girl with epilepsy in a pediatric hospital. Therapeutic drug monitoring with an assessment of the level of valproic acid in blood plasma against the background of joint use with carbapenem (ertapenem) allowed to revise and adjust the prescribed antibacterial therapy, and later allowed to adjust the daily dose of sodium valproate in a child with epilepsy. The change of the antibacterial drug was accompanied by an increase in the level of valproic acid in the blood plasma. The transition from intravenous administration of valproic acid to enteral administration of the drug was accompanied by a decrease in the concentration of valproic acid in blood plasma. The authors of the article presented data confirming the need for therapeutic drug monitoring in children receiving valproic acid and beta-lactam antibiotic from the carbapenem group - ertapenem, based on the known mechanisms of famacokinetic interaction, as well as in patients whose management tactics are planned to change the dosage form of valproic acid.
Full Text
![Restricted Access](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
About the authors
A. B. Strok
«Peoples' Friendship University of Russia (PFUR) named after Patrice Lumumba»; «Russian Children's Clinical Hospital is a Branch of the «N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation»
Author for correspondence.
Email: strok_ab@pfur.ru
Ph.D. (Med.), Assistant of Department of General and Clinical Pharmacology, Clinical Pharmacologist
Russian Federation, Moscow; MoscowM. S. Chenkurov
«Peoples' Friendship University of Russia (PFUR) named after Patrice Lumumba»
Email: chenkurov_ms@pfur.ru
Ph.D. (Biol.), Assistant of Department of General and Clinical Pharmacology
Russian Federation, MoscowM. N. Kostyleva
«Russian Children's Clinical Hospital is a Branch of the «N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation; "N.I. Pirogov Russian National Research Medical University" of the Ministry of Health of the Russian Federation
Email: mkostyleva@mail.ru
Ph.D. (Med.), Head of Department of Clinical Pharmacology, Clinical Pharmacologist; Associate Professor
Russian Federation, Moscow; MoscowD. A. Umutkuzina
City Clinical Hospital named after M.E. Zhadkevich
Email: umutkuzinada@gmail.com
Clinical Pharmacologist
Russian Federation, MoscowReferences
- Власов П.Н., Орехова, Н.В., Антонюк, М.В. и др. Эффек-тивность и безопасность препаратов вальпроевой кисло-ты с контролируемым высвобождением активного ве-щества у взрослых в реальной клинической практике с позиции фармакокинетического и фармакогенетического подхода. Неврология, нейропсихиатрия, психосоматика. 2017; 9(Эпилепсия): 11–20 (Vlasov P.N., Orehova, N.V., Antonjuk, M.V. i dr. Jef-fek-tivnost' i bezopasnost' preparatov val'proevoj kisloty s kontroliruemym vysvobozhdeniem aktivnogo veshhestva u vzroslyh v real'noj klinicheskoj praktike s pozicii farmakokineticheskogo i farmakogene-ticheskogo podhoda. Nevrologija, nejropsihiatrija, psihoso-matika. 2017; 9(Jepilepsija): 11–20).
- Rahman M., Nguyen H. Valproic Acid. [Updated 2022 Jul 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: https://www.ncbi.nlm.nih. gov/books/NBK559112.
- Rahman M., Awosika A.O., Nguyen H. Valproic Acid. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. PMID: 32644538.
- Park M.K., Lim K.S., Kim T.E. et al. Reduced valproic acid serum concentrations due to drug interactions with carbape-nem antibiotics: overview of 6 cases. Ther Drug Monit. 2012 Oct; 34(5): 599–603. doi: 10.1097/FTD.0b013e3182 60f7b3. PMID: 22929406.
- Chen I.L., Lee C.H., Hsiao S.C., Shih F.Y. Interactions between carbapenems and valproic acid among the patients in the intensive care units. J. Crit. Care. 2021 Apr; 62: 151–156. doi: 10.1016/j.jcrc.2020.12.005. Epub 2020 Dec 16. PMID: 33383308.
- Hernández-Ramos J.A., Caro-Telle J.M., Bruni-Montero M.Á., et al. Interaction between valproic acid and meropenem or ertapenem in patients with epilepsy: clinical relevance and results from pharmaceutical intervention. Farm Hosp. 2021 Sep 28; 45(6): 335–339. English. PMID: 34806574.
Supplementary files
![](/img/style/loading.gif)